Capivasertib, an AKT kinase inhibitor, as monotherapy or in combination with fulvestrant in patients with AKT1 (E17K)-mutant, ER-positive metastatic breast cancer
Smyth, LM Tamura, K Oliveira, M Ciruelos, EM Mayer, IA Sablin, MP Biganzoli, L Ambrose, HJ Ashton, Jack Barnicle, A
Smyth, LM
Tamura, K
Oliveira, M
Ciruelos, EM
Mayer, IA
Sablin, MP
Biganzoli, L
Ambrose, HJ
Ashton, Jack
Barnicle, A
Citations
Altmetric:
Abstract
Authors
Smyth, LM
Tamura, K
Oliveira, M
Ciruelos, EM
Mayer, IA
Sablin, MP
Biganzoli, L
Ambrose, HJ
Ashton, Jack
Barnicle, A
Cashell, DD
Corcoran, C
de Bruin, EC
Foxley, A
Hauser, J
Lindemann, JPO
Maudsley, R
McEwen, R
Moschetta, M
Pass, M
Rowlands, V
Schiavon, G
Banerji, U
Scaltriti, M
Taylor, BS
Chandarlapaty, S
Baselga, J
Hyman, DM
Tamura, K
Oliveira, M
Ciruelos, EM
Mayer, IA
Sablin, MP
Biganzoli, L
Ambrose, HJ
Ashton, Jack
Barnicle, A
Cashell, DD
Corcoran, C
de Bruin, EC
Foxley, A
Hauser, J
Lindemann, JPO
Maudsley, R
McEwen, R
Moschetta, M
Pass, M
Rowlands, V
Schiavon, G
Banerji, U
Scaltriti, M
Taylor, BS
Chandarlapaty, S
Baselga, J
Hyman, DM
Affiliation
Description
Date
2020
Publisher
Collections
Keywords
Type
Article
Citation
Smyth LM, Tamura K, Oliveira M, Ciruelos EM, Mayer IA, Sablin MP, et al. Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination With Fulvestrant in Patients With AKT1 (E17K)-Mutant, ER-Positive Metastatic Breast Cancer. Clin Cancer Res. 2020.